Larisa H. Cavallari

Clinical Pharmacogenetics Implementation Consortium Guideline for <i>CYP2D6</i>, <i>OPRM1</i>, and <i>COMT</i> Genotypes and Select Opioid Therapy

Kristine R. Crews, Andrew A. Monte, Rachel Huddart et al. · Clinical Pharmacology & Therapeutics · 2021 · 399 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

Nita A. Limdi, Mia Wadelius, Larisa H. Cavallari et al. · Blood · 2010 · 370 citations · Full text

Medicine, Genetics, Pharmacology +16

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees et al. · JACC: Cardiovascular Interventions · 2017 · 310 citations

Medicine, Cardiology, Pharmacology +16

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing

John J. Lima, Cameron D. Thomas, Julia M. Barbarino et al. · Clinical Pharmacology & Therapeutics · 2020 · 298 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study

Minoli A. Perera, Larisa H. Cavallari, Nita A. Limdi et al. · The Lancet · 2013 · 276 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15